July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

Royalty buys PTC royalty stream
Royalty Pharma plc (NASDAQ:RPRX) is spending $650 million to acquire from PTC Therapeutics Inc. (NASDAQ:PTCT) about 43% its royalties for spinal muscular atrophy therapy risdiplam, to which the biotech's entitled to 8-16% on worldwide net sales. The therapy’s PDUFA date is Aug. 24.

CureVac tops off $640M raise
CureVac

Read the full 510 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE